Hervycta 150 + Injection contains Trastuzumab 150 mg, a recombinant humanized monoclonal antibody targeting the HER2 receptor, which is overexpressed in certain types of breast and gastric cancers. Hervycta 150 + Injection is indicated for the treatment of HER2-positive metastatic breast cancer, early-stage breast cancer as adjuvant therapy, and HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma. By binding specifically to the extracellular domain of the HER2 receptor, Trastuzumab inhibits tumor cell proliferation and mediates antibody-dependent cellular cytotoxicity. The administration of Hervycta 150 + Injection requires intravenous infusion, typically initiated with a loading dose followed by maintenance doses at regular intervals as per oncological protocols. Prior to initiation, patients should be evaluated for cardiac function due to the potential risk of cardiotoxicity associated with Trastuzumab therapy. Monitoring during treatment includes periodic assessment of left ventricular ejection fraction and vigilance for infusion-related reactions. Hervycta 150 + Injection should be used under strict medical supervision, with dosage adjustments based on clinical response and tolerability. It is contraindicated in patients with known hypersensitivity to Trastuzumab or any of its excipients. This product represents a targeted therapeutic option aimed at improving clinical outcomes in HER2-positive malignancies.